U.S. Stem Cell, Inc. engages in the research, development, and commercialization of stem cell and regenerative treatments in the United States and internationally. The company develops MyoCell, an autologous muscle stem cell therapy which is preparing for phase II/III clinical trials for the treatment of heart damage in heart failure patients; MyoCell SDF-1, an autologous cell therapy which completed the IND application for the treatment of chronic damage in the heart and enhancement of blood vessel formation; and AdipoCell, a clinical protocol and kit which is preparing for clinical trials for the treatment of chronic ischemic cardiomyopathy. It also offers regenerative medicine solutions to veterinarians; and training programs for physicians to perform bone marrow derived stem cell protocols. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in November 2015. U.S. Stem Cell, Inc. was incorporated in 1999 and is headquartered in Sunrise, Florida.